State Street Corp Trims Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO)

State Street Corp decreased its holdings in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 4.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 671,376 shares of the company’s stock after selling 34,171 shares during the quarter. State Street Corp owned about 1.27% of ALX Oncology worth $1,222,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in ALX Oncology by 394.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock worth $39,000 after acquiring an additional 5,200 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in ALX Oncology during the 2nd quarter worth approximately $63,000. AQR Capital Management LLC raised its holdings in ALX Oncology by 50.7% in the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock valued at $109,000 after buying an additional 6,080 shares during the period. SG Americas Securities LLC grew its stake in ALX Oncology by 33.6% during the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after buying an additional 6,888 shares during the period. Finally, Algert Global LLC acquired a new stake in ALX Oncology in the 2nd quarter valued at $249,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

Insider Buying and Selling at ALX Oncology

In related news, Director Rekha Hemrajani purchased 30,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were acquired at an average price of $1.55 per share, with a total value of $46,500.00. Following the acquisition, the director now owns 33,000 shares in the company, valued at approximately $51,150. This trade represents a 1,000.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 33.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have commented on ALXO shares. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research note on Wednesday, December 18th. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of ALX Oncology in a research report on Wednesday, December 18th. Finally, Jefferies Financial Group downgraded shares of ALX Oncology from a “buy” rating to a “hold” rating and lowered their price objective for the company from $12.00 to $2.00 in a research report on Thursday, December 19th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

ALX Oncology Price Performance

Shares of NASDAQ:ALXO opened at $1.56 on Friday. The company has a market cap of $82.28 million, a PE ratio of -0.52 and a beta of 1.04. ALX Oncology Holdings Inc. has a fifty-two week low of $1.19 and a fifty-two week high of $17.83. The firm has a 50-day simple moving average of $1.52 and a 200 day simple moving average of $2.90. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.